Efficacy and Safety of Akkermansia Muciniphila AKM Lab-01 for Overweight and Obesity
NCT07331974 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2026-01-15
Summary
This study is designed as a preliminary investigation to evaluate the weight-loss efficacy and safety of AKM Lab-01 in an overweight or obese population. It is an interventional, radomized, double-blind, placebo-controlled clinical trial. Participants who meet the eligibility criteria will be randomly assigned to receive AKM Lab-01 or a matching placebo. The intervention will be administered once daily for 3 months. Baseline metrics, along with blood, urine, and stool samples, will be collected from participants, before and after the AKM Lab-01 intervention. The analysis will focus on changes in body weight, blood lipids, blood glucose, and gut metagenomic profiles (from stool samples). Furthermore, metabolomic analysis of blood and stool samples will be conducted to explore the potential machanisms through which AMK Lab-01 influences body weight.
Conditions
- Overweight , Obesity
Interventions
- DRUG
-
AKM Lab-01
A specific dose of AKM Lab-01 will be administered orally once daily for a period of 3 months.
- DRUG
-
Placebo will be administered orally once daily for a period of 3 months.
Sponsors & Collaborators
-
Moon (Guangzhou) Biotechnology Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2027-01-31
- Completion
- 2027-05-31
Countries
- China
Study Locations
More Related Trials
-
A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.
NCT07121153 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
NCT06867718 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
NCT04605861 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
NCT07279194 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
NCT06679959 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
NCT06714955 ·Status: COMPLETED ·Phase: PHASE1
-
Study of NGM395 in Adult Participants
NCT04187339 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of IQP- AK-102 in Reducing Body Weight
NCT01905956 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07002905 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
NCT07239973 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants
NCT07294235 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
NCT06532578 ·Status: COMPLETED ·Phase: PHASE2
-
Innovative Functional Product for Overweight and Obesity
NCT07044167 ·Status: COMPLETED ·Phase: NA
-
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
NCT06973681 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
NCT06885021 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight
NCT07110766 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
NCT07017179 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of IQP-AK-102 in Reducing Appetite
NCT02041754 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
NCT06938269 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
NCT06118021 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
NCT07103382 ·Status: RECRUITING ·Phase: NA
-
Evaluation of a Supplement for Weight Management in Obese and Overweight Individuals
NCT03812211 ·Status: COMPLETED ·Phase: NA
-
A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.
NCT06481098 ·Status: COMPLETED ·Phase: PHASE1
-
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
NCT07219589 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
NCT06606483 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2